Allergan Inc., of Irvine, Calif., said UK regulators approved Botox (botulinum toxin type A) for the treatment of ankle disability due to lower limb spasticity associated with stroke in adults. Read More
Domain Therapeutics SA, of Strasbourg, France, and Xoma Corp., of Berkeley, Calif., entered a multistep collaboration involving Xoma’s research on allosteric modulation and Domain’s Dtect-All, a platform that has discovered small-molecule allosteric modulators for a wide range of G protein-coupled receptors (GPCRs). Read More
Hemispherx Biopharma Inc., of Philadelphia, presented a summary of the results of its Phase I/II study at the American Society for Microbiology Biodefense Conference in Washington, showing that when Flumist, a seasonal influenza vaccine, was administered intranasally in conjunction with the company’s Ampligen, a Toll-like receptor 3 agonist, 92 percent of subjects elaborated specific IgA antibodies against at least one of the homologous seasonal vaccine strains. Read More
Auspex Pharmaceuticals Inc., of La Jolla, Calif., raised the proposed deal size of its initial public offering. The company plans to raise $66 million by offering 6 million shares in a range of $10 to $12, up from 5.5 million shares at the same range. Read More
Seeing the biosimilar debate as a way to improve pharmacovigilance for all biologics, several biosimilar makers are now pushing for state notification regulations that would lead to transparent and more accurate patient health records. Read More
Bidding to become the second European company to secure regulatory approval for gene therapy, Molmed SpA plans to seek a conditional marketing authorization in Europe for its genetically engineered cell therapy TK treatment for high-risk acute leukemia patients in the current quarter. Read More
LONDON – Spinifex Pharmaceuticals announced the publication of positive Phase IIa data for EMA401, a first-in-class oral treatment for chronic neuropathic pain, and said it is now in the process of raising $40 million to $50 million to fund a broad Phase IIb program. Read More
In his typical self-effacing manner, National Institutes of Health (NIH) director Francis Collins poked fun at his own “acronym acrobatics” when introducing the Accelerating Medicines Partnership (AMP) to reporters in Washington on Tuesday. “We’re amped up,” he joked, “and we want to amplify for you why we are so excited!” Read More
Furiex Pharmaceuticals Inc.’s Phase III win with lead compound eluxadoline in diarrhea-predominant irritable bowel syndrome (IBS-D) turned investors’ eyes to next moves, including a potential partner for the locally acting mu opioid receptor agonist and delta opioid receptor antagonist or a possible buyout, given the success earlier of its approved diabetes therapy Nesina (alogliptin benzoate). Read More
